Skip to content

Study · Animal study (in vivo) · dog · 1991

6 results

Intranasal activity of the growth hormone releasing peptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in conscious dogs.

Nelson AH, Walker RF, Codd EE, Barone FC

Life sciences1 Jan 1991Cited by 3 (Europe PMC)

PMID2046459 (opens in a new tab)DOI10.1016/0024-3205(91)90344-b (opens in a new tab)PepBankPUB-02046459
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In conscious dogs, intranasal GHRP‑6 increased plasma GH in a dose-related manner.

    In plain wordsIn dogs, intranasal GHRP‑6 increased blood GH with increasing dose.

    Peptide
    GHRP-6
    Outcome
    IncreaseDose-related GH release
    Study

    dogn: not reported in source

    conscious dogs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intranasalAs given in this study (dog).

    Source sentences

    Summary
    Intranasal administration of GHRP-6 increased plasma growth hormone levels in the conscious dog in a dose-related manner.
    1 context sentence
    Summary · context
    This series of experiments was conducted to evaluate the growth hormone (GH) releasing activity of intranasally administered His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6, SK&F 110679) in conscious dogs.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In conscious dogs, intranasal GHRP‑6 at 0.25 mg/kg produced GH levels of 11.3 ng/ml.

    In plain wordsIn dogs, the lower intranasal GHRP‑6 dose increased blood GH.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH at lower intranasal dose
    Study

    dogn: not reported in source

    conscious dogs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.25 mg/kg · intranasalAs given in this study (dog).

    Measurements

    GH
    11.3 ng/ml
    0.25 mg/kg intranasal

    Source sentences

    Summary
    Doses of 0.25 and 0.5 mg/kg produced GH levels of 11.3 +/- 4.8 ng/ml and 28.6 +/- 8.0 ng/ml, respectively.
    1 context sentence
    Summary · context
    This series of experiments was conducted to evaluate the growth hormone (GH) releasing activity of intranasally administered His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6, SK&F 110679) in conscious dogs.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In conscious dogs, intranasal GHRP‑6 at 0.5 mg/kg produced GH levels of 28.6 ng/ml.

    In plain wordsIn dogs, the higher intranasal GHRP‑6 dose increased blood GH.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH at higher intranasal dose
    Study

    dogn: not reported in source

    conscious dogs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.5 mg/kg · intranasalAs given in this study (dog).

    Measurements

    GH
    28.6 ng/ml
    0.5 mg/kg intranasal

    Source sentences

    Summary
    Doses of 0.25 and 0.5 mg/kg produced GH levels of 11.3 +/- 4.8 ng/ml and 28.6 +/- 8.0 ng/ml, respectively.
    1 context sentence
    Summary · context
    This series of experiments was conducted to evaluate the growth hormone (GH) releasing activity of intranasally administered His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6, SK&F 110679) in conscious dogs.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In conscious dogs, GH peaked 15 minutes after intranasal GHRP‑6 and remained elevated for up to 105 minutes.

    In plain wordsIn dogs, GH rose after intranasal GHRP‑6 and remained elevated beyond the peak.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH response timing
    Study

    dogn: not reported in source

    conscious dogs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intranasalAs given in this study (dog).

    Source sentences

    Summary
    Peak levels were observed 15 minutes after dosing and GH levels were elevated for up to 105 minutes after intranasal dosing.
    1 context sentence
    Summary · context
    This series of experiments was conducted to evaluate the growth hormone (GH) releasing activity of intranasally administered His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6, SK&F 110679) in conscious dogs.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In conscious dogs, intravenous GHRP‑6 at 0.5 mg/kg produced peak plasma GH of 60.8 ng/ml.

    In plain wordsIn dogs, intravenous GHRP‑6 increased blood GH.

    Peptide
    GHRP-6
    Outcome
    IncreasePeak GH after intravenous dose
    Study

    dogn: not reported in source

    conscious dogs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.5 mg/kg · intravenousAs given in this study (dog).

    Measurements

    Peak GH
    60.8 ng/ml
    0.5 mg/kg intravenous

    Source sentences

    Summary
    When GHRP-6 was given by the intravenous route, a maximal dose of 0.5 mg/kg, produced a peak plasma GH concentration of 60.8 +/- 10.5 ng/ml.
    1 context sentence
    Summary · context
    This series of experiments was conducted to evaluate the growth hormone (GH) releasing activity of intranasally administered His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6, SK&F 110679) in conscious dogs.
  6. 06AnimalAnimal study (in vivo)Activity measurement

    In conscious dogs, GH response curves gave estimated intranasal GHRP‑6 bioavailability of 34.4 to 44.9% relative to intravenous dosing.

    In plain wordsIn dogs, GH responses suggested lower GHRP‑6 availability after intranasal than intravenous dosing.

    Peptide
    GHRP-6
    Outcome
    Not applicableEstimated intranasal bioavailability
    Study

    dogn: not reported in source

    conscious dogs
    Comparator
    Intravenous GHRP-6
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intranasalAs given in this study (dog).

    Measurements

    Estimated bioavailability
    34.4 to 44.9%
    intranasal relative to intravenous GH response

    Source sentences

    Summary
    Using the intravenous and intranasal GH response data (i.e., area under the time-response curves), the intranasal bioavailability of GHRP-6 was estimated to be 34.4 to 44.9%.
    1 context sentence
    Summary · context
    This series of experiments was conducted to evaluate the growth hormone (GH) releasing activity of intranasally administered His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6, SK&F 110679) in conscious dogs.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:59 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.